Inovio Pharmaceuticals, Inc.INONASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank36
3Y CAGR-32.9%
5Y CAGR-8.6%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-32.9%/yr
vs +22.2%/yr prior
5Y CAGR
-8.6%/yr
Recent deceleration
Acceleration
-55.1pp
Decelerating
Percentile
P36
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
4 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $83.90M | -25.5% |
| 2024 | $112.62M | -22.2% |
| 2023 | $144.77M | -47.9% |
| 2022 | $277.84M | -8.3% |
| 2021 | $302.99M | +130.4% |
| 2020 | $131.49M | +14.1% |
| 2019 | $115.22M | -7.5% |
| 2018 | $124.57M | -1.8% |
| 2017 | $126.86M | +12.7% |
| 2016 | $112.60M | - |